Cellumen signs partnership agreement with ADDF

The main objective of the partnership is for Cellumen to develop a panel of Cellular Systems Biology (CSB) assays, as well as biosensors of key protein:protein interactions, that reveal the activity of multiple targets and pathways implicated in Alzheimer’s disease in an intact, functioning cellular system.

Lansing Taylor, CEO of Cellumen, said: “Our alliance with the Alzheimer’s Drug Discovery Foundation (ADDF) allows Cellumen to implement its Cellular Systems Biology expertise to enable lead discovery for Alzheimer’s disease. Our ability to use the cell as an integrated, interactive network of genes, proteins, and metabolites sets us apart, and enables us to address this unmet medical need.”